Annovis Bio Inc (ANVS) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Annovis Bio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Annovis Bio Inc 's ROA in the second quarter of 2026?
Annovis Bio Inc recorded a cumulative net loss of $-50 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -258.78%.
However, within the Healthcare sector 877 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4503, from total ROA ranking in the first quarter of 2026 at 5051.
Annovis Bio Inc. Poised for Breakthroughs in Alzheimer s Treatment as FDA Accepts Phase 3 Study Protocol Amidst Financial ChallengesIn a significant development for the biotechnology sector, Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on combating neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), has announced that the U.S. Food and Drug Administration (FDA) has accepted its updated protocol for a pivotal Phase 3 study aimed at Alzheimer’s disease. Slated to commence in January 2025, this study represents a critical step in the development pathway for Annovis’s innovative therapies.The acceptance by the FDA marks a watershed moment for Annovis, particularly as the company navigates the increasingly competitive landscape of neurodegenerative treatments. Having faced substantial financial headwinds, including a cumulative net loss of $41 million over the 12 months ending in the third quarter of 2024, Annovis s financial indicators reveal a negative return on assets (ROA) of -472.52%. To put this into perspective, during the same period, 912 other companies within the healthcare sector demonstrated a higher ROA, reflecting the challenging economic climate within the industry.
In the realm of biopharmaceutical innovation, neurodegenerative diseases, including Alzheimer s, represent one of the most significant challenges facing modern medicine. With millions affected globally, the medical community and researchers are actively pursuing novel therapeutic strategies to alleviate the burden of these conditions. One company leading the charge in this vital area is Annovis Bio Inc. (NYSE: ANVS), whose pioneering approach seeks to develop safe and effective drugs designed to improve cognition and enhance quality of life for individuals grappling with neurodegenerative disorders. Annovis Bio Inc.: Mission and Vision Founded with the mission to address the unmet medical needs associated with neurodegenerative diseases, Annovis Bio is dedicated to pioneering comprehensive and innovative treatments. Their primary focus is on developing drugs that not only alleviate symptoms but also target the underlying mechanisms of diseases such as Alzheimer s and Parkinson s. The company’s research has led to promising findings, particularly in the realm of cognition enhancement.
Annovis Bio Marks a Milestone with Landmark TBI Treatment PatentThe field of neurodegenerative disease treatment has witnessed a significant breakthrough as Annovis Bio Inc. (NYSE: ANVS) secures a U.S. patent for its revolutionary treatment for Traumatic Brain Injury (TBI). This achievement is expected to provide novel therapeutic approaches to address the pressing challenges in this domain.TBI has emerged as a major health concern globally, with millions of people suffering from its debilitating consequences. Recognizing the urgent need for effective treatment options, Annovis Bio has invested considerable resources in developing groundbreaking therapies for neurodegenerative diseases such as Alzheimer s and Parkinson s. This recent patent approval underscores the company s commitment to advancing medical science and improving patient outcomes.
Annovis Bio Inc. (NYSE: ANVS) has made significant advancements in the field of neurodegenerative drug therapy, particularly in the treatment of Parkinson s disease (PD) and Alzheimer s disease (AD). With recent data from Phase III studies, FDA approvals, and strategic developments, Annovis Bio has firmly established itself as a pioneering company in the healthcare sector. This article will highlight some of the key achievements and market performance of Annovis Bio, showcasing its potential for future success.Enhancing Motor, Cognitive, and Non-Motor Activities in Parkinson s DiseaseOne of Annovis Bio s breakthroughs is the development of buntanetap, a drug known for enhancing motor and cognitive functions, as well as non-motor activities in patients with early Parkinson s disease. The results from Phase III studies have demonstrated the effectiveness of buntanetap in improving multiple aspects of the disease, providing hope for better quality of life for patients.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
